GW Pharmaceuticals PLC-ADR GWPH 1.14% shares initially jumped Monday after disappointing data from a leading drug candidate sent shares of Zynerba Pharmaceuticals Inc ZYNE 1.43%plummeting more than 55 percent. However, while GW may now have less competition in the mix, investors soon realized the dangerous potential implications of the Zynerba news.
After dropping 2.1 percent Monday, GW shares opened Tuesday’s session down another 6.5 percent. Maxim Group analyst Gabrielle Zhou says investors have a right to be concerned about Zynerba’s ZYN002 failing to achieve both primary and secondary endpoints in a phase II epilepsy study.
“GW initially rallied (one less competitor), however, it closed down 2-3% as the reality of a CBD epilepsy failure now worries investors that GW’s botanically derived CBD’s benefit may be moderate at best,” Zhou wrote Tuesday.
Given the fact that GW’s stock has rallied 86 percent since the beginning of 2016, Zhou said investors have a right to be concerned about the stock’s steep valuation.
But while Zhou saw the Zynerba news as meaningful enough to downgrade GW Pharmaceuticals stock from Buy to Hold and remove her price target, other GW bulls were unfazed.
Cantor Fitzgerald analyst Elemer Piros said the updates GW provided on its recent investor call related to Epidiolex regulatory submissions and pre-commercialization initiatives suggest the drug is on-track for its rolling NDA submission to be completed by the end of October.
“Given the greater visibility into a potential approval we have adjusted…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
